Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment

Philip A. Philip, Margaret Mooney, Deborah Jaffe, Gail Eckhardt, Malcolm Moore, Neal Meropol, Leisha Emens, Eileen O'Reilly, Murray Korc, Lee Ellis, Jacqueline Benedetti, Mace Rothenberg, Christopher Willett, Margaret Tempero, Andrew Lowy, James Abbruzzese, Diane Simeone, Sunil Hingorani, Jordan Berlin, Joel Tepper

Research output: Contribution to journalArticle

178 Citations (Scopus)

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer mortality, despite significant improvements in diagnostic imaging and operative mortality rates. The 5-year survival rate remains less than 5% because of microscopic or gross metastatic disease at time of diagnosis. The Clinical Trials Planning Meeting in pancreatic cancer was convened by the National Cancer Institute's Gastrointestinal Cancer Steering Committee to discuss the integration of basic and clinical knowledge in the design of clinical trials in PDAC. Major emphasis was placed on the enhancement of research to identify and validate the relevant targets and molecular pathways in PDAC, cancer stem cells, and the microenvironment. Emphasis was also placed on developing rational combinations of targeted agents and the development of predictive biomarkers to assist selection of patient subsets. The development of preclinical tumor models that are better predictive of human PDAC must be supported with wider availability to the research community. Phase III clinical trials should be implemented only if there is a meaningful clinical signal of efficacy and safety in the phase II setting. The emphasis must therefore be on performing well-designed phase II studies with uniform sets of basic entry and evaluation criteria with survival as a primary endpoint. Patients with either metastatic or locally advanced PDAC must be studied separately.

Original languageEnglish
Pages (from-to)5660-5669
Number of pages10
JournalJournal of Clinical Oncology
Volume27
Issue number33
DOIs
StatePublished - Nov 20 2009
Externally publishedYes

Fingerprint

National Cancer Institute (U.S.)
Pancreatic Neoplasms
Adenocarcinoma
Clinical Trials
Stem Cell Niche
Therapeutics
Phase III Clinical Trials
Gastrointestinal Neoplasms
Neoplastic Stem Cells
Mortality
Diagnostic Imaging
Research
Patient Selection
Neoplasms
Survival Rate
Biomarkers
Safety
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Philip, P. A., Mooney, M., Jaffe, D., Eckhardt, G., Moore, M., Meropol, N., ... Tepper, J. (2009). Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. Journal of Clinical Oncology, 27(33), 5660-5669. https://doi.org/10.1200/JCO.2009.21.9022

Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. / Philip, Philip A.; Mooney, Margaret; Jaffe, Deborah; Eckhardt, Gail; Moore, Malcolm; Meropol, Neal; Emens, Leisha; O'Reilly, Eileen; Korc, Murray; Ellis, Lee; Benedetti, Jacqueline; Rothenberg, Mace; Willett, Christopher; Tempero, Margaret; Lowy, Andrew; Abbruzzese, James; Simeone, Diane; Hingorani, Sunil; Berlin, Jordan; Tepper, Joel.

In: Journal of Clinical Oncology, Vol. 27, No. 33, 20.11.2009, p. 5660-5669.

Research output: Contribution to journalArticle

Philip, PA, Mooney, M, Jaffe, D, Eckhardt, G, Moore, M, Meropol, N, Emens, L, O'Reilly, E, Korc, M, Ellis, L, Benedetti, J, Rothenberg, M, Willett, C, Tempero, M, Lowy, A, Abbruzzese, J, Simeone, D, Hingorani, S, Berlin, J & Tepper, J 2009, 'Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment', Journal of Clinical Oncology, vol. 27, no. 33, pp. 5660-5669. https://doi.org/10.1200/JCO.2009.21.9022
Philip, Philip A. ; Mooney, Margaret ; Jaffe, Deborah ; Eckhardt, Gail ; Moore, Malcolm ; Meropol, Neal ; Emens, Leisha ; O'Reilly, Eileen ; Korc, Murray ; Ellis, Lee ; Benedetti, Jacqueline ; Rothenberg, Mace ; Willett, Christopher ; Tempero, Margaret ; Lowy, Andrew ; Abbruzzese, James ; Simeone, Diane ; Hingorani, Sunil ; Berlin, Jordan ; Tepper, Joel. / Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. In: Journal of Clinical Oncology. 2009 ; Vol. 27, No. 33. pp. 5660-5669.
@article{63d6a6b99c1042a291a79da9d316af70,
title = "Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment",
abstract = "Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer mortality, despite significant improvements in diagnostic imaging and operative mortality rates. The 5-year survival rate remains less than 5{\%} because of microscopic or gross metastatic disease at time of diagnosis. The Clinical Trials Planning Meeting in pancreatic cancer was convened by the National Cancer Institute's Gastrointestinal Cancer Steering Committee to discuss the integration of basic and clinical knowledge in the design of clinical trials in PDAC. Major emphasis was placed on the enhancement of research to identify and validate the relevant targets and molecular pathways in PDAC, cancer stem cells, and the microenvironment. Emphasis was also placed on developing rational combinations of targeted agents and the development of predictive biomarkers to assist selection of patient subsets. The development of preclinical tumor models that are better predictive of human PDAC must be supported with wider availability to the research community. Phase III clinical trials should be implemented only if there is a meaningful clinical signal of efficacy and safety in the phase II setting. The emphasis must therefore be on performing well-designed phase II studies with uniform sets of basic entry and evaluation criteria with survival as a primary endpoint. Patients with either metastatic or locally advanced PDAC must be studied separately.",
author = "Philip, {Philip A.} and Margaret Mooney and Deborah Jaffe and Gail Eckhardt and Malcolm Moore and Neal Meropol and Leisha Emens and Eileen O'Reilly and Murray Korc and Lee Ellis and Jacqueline Benedetti and Mace Rothenberg and Christopher Willett and Margaret Tempero and Andrew Lowy and James Abbruzzese and Diane Simeone and Sunil Hingorani and Jordan Berlin and Joel Tepper",
year = "2009",
month = "11",
day = "20",
doi = "10.1200/JCO.2009.21.9022",
language = "English",
volume = "27",
pages = "5660--5669",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "33",

}

TY - JOUR

T1 - Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment

AU - Philip, Philip A.

AU - Mooney, Margaret

AU - Jaffe, Deborah

AU - Eckhardt, Gail

AU - Moore, Malcolm

AU - Meropol, Neal

AU - Emens, Leisha

AU - O'Reilly, Eileen

AU - Korc, Murray

AU - Ellis, Lee

AU - Benedetti, Jacqueline

AU - Rothenberg, Mace

AU - Willett, Christopher

AU - Tempero, Margaret

AU - Lowy, Andrew

AU - Abbruzzese, James

AU - Simeone, Diane

AU - Hingorani, Sunil

AU - Berlin, Jordan

AU - Tepper, Joel

PY - 2009/11/20

Y1 - 2009/11/20

N2 - Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer mortality, despite significant improvements in diagnostic imaging and operative mortality rates. The 5-year survival rate remains less than 5% because of microscopic or gross metastatic disease at time of diagnosis. The Clinical Trials Planning Meeting in pancreatic cancer was convened by the National Cancer Institute's Gastrointestinal Cancer Steering Committee to discuss the integration of basic and clinical knowledge in the design of clinical trials in PDAC. Major emphasis was placed on the enhancement of research to identify and validate the relevant targets and molecular pathways in PDAC, cancer stem cells, and the microenvironment. Emphasis was also placed on developing rational combinations of targeted agents and the development of predictive biomarkers to assist selection of patient subsets. The development of preclinical tumor models that are better predictive of human PDAC must be supported with wider availability to the research community. Phase III clinical trials should be implemented only if there is a meaningful clinical signal of efficacy and safety in the phase II setting. The emphasis must therefore be on performing well-designed phase II studies with uniform sets of basic entry and evaluation criteria with survival as a primary endpoint. Patients with either metastatic or locally advanced PDAC must be studied separately.

AB - Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer mortality, despite significant improvements in diagnostic imaging and operative mortality rates. The 5-year survival rate remains less than 5% because of microscopic or gross metastatic disease at time of diagnosis. The Clinical Trials Planning Meeting in pancreatic cancer was convened by the National Cancer Institute's Gastrointestinal Cancer Steering Committee to discuss the integration of basic and clinical knowledge in the design of clinical trials in PDAC. Major emphasis was placed on the enhancement of research to identify and validate the relevant targets and molecular pathways in PDAC, cancer stem cells, and the microenvironment. Emphasis was also placed on developing rational combinations of targeted agents and the development of predictive biomarkers to assist selection of patient subsets. The development of preclinical tumor models that are better predictive of human PDAC must be supported with wider availability to the research community. Phase III clinical trials should be implemented only if there is a meaningful clinical signal of efficacy and safety in the phase II setting. The emphasis must therefore be on performing well-designed phase II studies with uniform sets of basic entry and evaluation criteria with survival as a primary endpoint. Patients with either metastatic or locally advanced PDAC must be studied separately.

UR - http://www.scopus.com/inward/record.url?scp=73949107880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73949107880&partnerID=8YFLogxK

U2 - 10.1200/JCO.2009.21.9022

DO - 10.1200/JCO.2009.21.9022

M3 - Article

VL - 27

SP - 5660

EP - 5669

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 33

ER -